Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company

    Vasogen to also Raise $7.5 Million in Non-Dilutive Financing from
    Cervus LP

    MISSISSAUGA, ON, Aug. 17 /CNW/ - Vasogen Inc. (NASDAQ:  VSGN; TSX:VAS) and
IntelliPharmaCeutics (IPC) announced today that they have entered into a
definitive agreement, subject to shareholder and regulatory approvals, whereby
Vasogen will combine with IPC under a plan of arrangement and merger to
continue as a publicly-traded entity to be called IntelliPharmaCeutics
International Ltd. IPC is a privately-held specialty pharmaceutical company
that is focused on developing and manufacturing new and generic
controlled-release pharmaceutical products using its broadly applicable,
proprietary delivery technologies. Currently, IPC has 15 product candidates in
its development pipeline several of which are partnered with third-party drug
companies. IPC's lead product candidates include Dexmethylphenidate XR, a
generic version of the marketed drug Focalin XR(R), which is partnered with
Par Pharmaceutical and is currently the subject of an Abbreviated New Drug
Application (ANDA) filing with the U.S. Food and Drug Administration (FDA),
and Carvedilol CR, a generic version of the brand name drug Coreg CR, an
internal pipeline product now ready for entry into pivotal bioequivalence
    Separately, Vasogen has also entered into an arrangement agreement with
Cervus LP (TSXV:CVL.UN), an Alberta based limited partnership, that will
reorganize Vasogen prior to completion of the transaction with IPC and which
will provide gross proceeds to Vasogen of approximately $7.5 million in
non-dilutive capital.
    "The combination of IPC and Vasogen, along with proceeds from this
non-dilutive financing, will provide our shareholders an exciting opportunity
to have an equity interest in a strong, dynamic, company with experienced
management, a broad development pipeline, and significant near-term revenue
potential," commented Dr. Eldon Smith, Vasogen's Chairman. "Following a
diligent exploratory and strategic review process, we believe that this
combination clearly fulfils the Board's mandate of identifying a strategic
option that has the potential to provide long-term value to our shareholders.
Important contributing factors to our decision included IPC's leadership and
long history of experience in drug development and the validation of their
drug delivery technologies in attracting the interest and partnership of
established pharmaceutical companies."
    "This combination provides an ideal opportunity for IPC to make the
transition to being a successful public specialty pharmaceutical company. With
a diversified portfolio of product assets at varying development stages,
shareholders of both organizations will have the opportunity to benefit
greatly from multiple value-creating events for years to come," stated Dr. Isa
Odidi, Chairman and CEO of IPC. "The resources of the combined companies will
allow us to focus on and accelerate the near-term commercialization of our
lead product candidates, Dexmethylphenidate XR and Carvedilol CR, as well as a
number of other important compounds in our product pipeline, including an
early-stage innovation directed to long-acting, abuse-resistant narcotics."
    Based on a number of factors, including the recommendation of a special
committee of directors of Vasogen, as well as a fairness opinion rendered by
JMP Securities LLC, Vasogen's financial advisor for the transaction with IPC,
Vasogen's Board of Directors unanimously recommend that shareholders approve
the transactions. Vasogen's advisor for the non-dilutive financing transaction
with Cervus LP is PricewaterhouseCoopers Corporate Finance Inc.

    Details of the Proposed Transactions

    The proposed transactions involve a corporate reorganization to be
completed pursuant to a court approved plan of arrangement. Vasogen will
transfer its assets and liabilities - including the proceeds from the Cervus
transaction but excluding the Company's tax basis - to a new subsidiary to be
incorporated. As part of the plan of arrangement, Cervus LP unitholders, on
completion of the transaction, will own 100% of the shares of the current
Vasogen entity. As part of the transaction, Vasogen security holders will have
exchanged their Vasogen securities for securities of a separate new subsidiary
of Vasogen that will own the assets of Vasogen and that entity shall have
subsequently amalgamated with a new IPC corporation to be created. IPC
shareholders will either exchange their shares directly for shares of such new
IPC corporation or receive shares of the resulting amalgamated company
pursuant to a merger of IPC's U.S. subsidiaries.
    IPC's shareholders are expected to own approximately 86% of the
outstanding common shares of the combined company and Vasogen's shareholders
are expected to own approximately 14% of the outstanding common shares. IPC
and Vasogen are currently assessing the appropriate capital structure for the
combined company moving forward, which will take into consideration of a
number of factors, including input from discussions with NASDAQ and the TSX.
Following this assessment, IPC and Vasogen plan to outline their proposal and
plans in a joint proxy circular to be provided to shareholders, which is
expected to be filed in the coming weeks. Dr. Isa Odidi and Dr. Amina Odidi
would together beneficially own approximately 55.3% of the combined company.
IPC's second largest shareholder, Par Pharmaceutical, which acquired an equity
interest in IPC in 2007 at the same time as it entered into a product
commercialization agreement with IPC for the development and commercialization
of four product candidates, would effectively own approximately 3.6% of the
combined company after closing. The combined company will retain ownership of
Vasogen's intellectual property; however, the development focus is expected to
be principally on IPC's current product pipeline.
    Completion of the transaction is subject to a number of conditions
including approval of Vasogen and IPC shareholders and Cervus unitholders,
Vasogen maintaining certain minimum cash levels, receipt of court and other
regulatory approvals, and other customary closing conditions. The Boards of
Directors of each of Vasogen, IPC, and Cervus GP Inc. have unanimously
approved the agreements pursuant to which the parties will give effect to the
plan of arrangement. Vasogen and IPC expect to issue a joint proxy circular to
their respective shareholders with respect to this transaction in the coming
weeks and expect their respective shareholder voting to occur in October 2009.
IPC believes that this transaction will be completed without giving rise to a
tax liability for IPC shareholders. The combined company plans to continue
Vasogen's quotation on NASDAQ and its listing on the TSX; however, there can
be no assurance that the new company's shares will be quoted on NASDAQ or
listed on the TSX. The auditor of the combined entity will be IPC's present
auditor, Deloitte & Touche LLP.

    IPC Overview

    IPC is a privately-held drug delivery innovator, whose predecessor in
name was founded in 1998, which develops both new and generic
controlled-release pharmaceutical products. IPC has approximately 25 employees
and operates from a 25,000 sq. ft. research laboratory and manufacturing
scale-up facility in Toronto.
    Using its proprietary technologies, IPC's strategy involves the
development of products for partners and the development and manufacture of
its own proprietary products. Currently, IPC has 15 products in its pipeline
at varying stages of development and regulatory review. Several of these
product candidates have been partnered under drug development arrangements
which have or provide for milestone and success fees, support for internal
development costs, coverage of clinical trial costs, coverage of patent
litigation costs, and royalties or profit sharing on product sales. IPC
applies its proprietary delivery platform technology and expertise in
pharmaceutics, drug delivery, and drug manufacture with the goal of minimizing
the risk, time, and manufacturing cost of bringing the finished product to
    IPC's lead products in the generic, controlled-release pharmaceutical
category are Dexmethylphenidate XR (dexmethylphenidate hydrochloride), a
generic version of Focalin XR(R), which is an extended-release capsule for the
treatment of Attention Deficit Hyperactivity Disorder, and Carvedilol CR
(carvedilol phosphate), a generic version of Coreg CR(R), which is an extended
release capsule for the treatment of high blood pressure. In 2008, Focalin(R),
including Focalin XR(R), had U.S. sales of approximately U.S. $350 million,
and Coreg(R), including Coreg CR(R), had U.S. sales of approximately U.S.
$300M million. IPC and its development partner, Par Pharmaceutical, filed an
ANDA for a generic Focalin XR(R) product with the FDA in May 2007, received
notification of the application's acceptance for filing in August 2007 and the
application continues to be processed by the FDA. If approved by the FDA, IPC
anticipates that its generic version of Focalin XR(R) may achieve
first-to-file status at a specified strength level. One of IPC's key
non-generic products is an abuse- and alcohol-resistant, controlled-release
oral oxycodone formulation. This product is covered by pending patent
applications for its novel ReXista(TM) abuse- and alcohol-resistant drug
delivery technology. The product is a unique dosage form, designed to be
resistant to abuse by oral ingestion when crushed or chewed, by injection when
combined with solvents, and by nasal inhalation when crushed or powdered. The
abuse of this important pain relief drug has been well documented over many
years. In 2008, Oxycodone had U.S. sales of approximately U.S. $2 billion. The
product is also designed to resist release of the entire dose when consumed
with alcohol, a significant problem with some opioid drugs, such as

    Management and Organization

    Dr. Isa Odidi will be the Chairman of the Board of Directors of the
combined company. Other members of the Board will include Dr. Amina Odidi,
John Allport, Dr. Kenneth Keirstead, Mr. Bahadur Madhani, and Dr. Eldon Smith,
Vasogen's nominee.
    Dr. Isa Odidi, who is currently Chairman and CEO of IPC, co-founded IPC
along with Dr. Amina Odidi, the President and COO, and together they comprise
its majority shareholders. From 1995 to 1998, Dr. Odidi held positions, first
as Director, then as Vice President, of Research of Drug Development and New
Technologies at Biovail Corporation International (now Biovail Corporation), a
drug delivery company. Prior to 1995, Dr. Odidi held senior positions in
academia and in the pharmaceutical and health care industries. He currently
holds a Chair as Professor of Pharmaceutical Technology at the Toronto
Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor
at the Institute for Molecular Medicine, California, U.S. Dr. Odidi received
his B.Sc. degree in Pharmacy, and his M.Sc. in Pharmaceutical Technology, and
his Ph.D. in Pharmaceutics from the University of London. He is also a
graduate of the Western Executive Management Program and obtained his MBA from
the Rotman School of Business at the University of Toronto.
    Dr. Amina Odidi, who is currently President and COO of IPC, also has
extensive experience developing and applying proprietary technologies to the
development of controlled-release drug products for third-party pharmaceutical
companies. She received her B.Sc. in Pharmacy, and her M.S. in
Biopharmaceutics and her Ph.D. in Pharmaceutics from the University of London.

    Conference Call Information

    A conference call will be conducted on August 17, 2009, at 9:00 a.m.
Eastern Time. To participate by telephone, call 416-340-8018 or
1-866-225-0198, ten minutes prior to the start of the call. To participate via
webcast, please go to A re-broadcast of the conference call
will be available at or by calling 416-695-5800 or
1-800-408-3053, pass code 5484653.

    Vasogen Safe Harbor Statement

    Certain statements in this document constitute "forward-looking
statements" within the meaning of the United States Private Securities
Litigation Reform Act of 1995 and/or "forward-looking information" under the
Securities Act (Ontario). These statements include, without limitation, our
plans to complete the business combination described in this press release
resulting from our strategic review, statements regarding the status of
development, or expenditures relating to our business, plans to fund our
current activities, statements concerning our partnering activities, health
regulatory submissions, strategy, future operations, future financial
position, future revenues and projected costs. In some cases, you can identify
forward-looking statements by terminology such as "may", "will", "should",
"expects", "plans", "anticipates", "believes", "estimated", "predicts",
"potential", "continue", "intends", "could", or the negative of such terms or
other comparable terminology. We made a number of assumptions in the
preparation of these forward-looking statements. You should not place undue
reliance on our forward-looking statements, which are subject to a multitude
of risks and uncertainties that could cause actual results, future
circumstances or events to differ materially from those projected in the
forward-looking statements. These risks include, but are not limited to, the
outcome of our strategic review, securing and maintaining corporate alliances,
the need for additional capital and the effect of capital market conditions
and other factors, including the current status of our programs, on capital
availability, the potential dilutive effects of any financing and other risks
detailed from time to time in our public disclosure documents or other filings
with the Canadian and U.S. securities commissions or other securities
regulatory bodies. Additional risks and uncertainties relating to our Company
and our business can be found in the "Risk Factors" section of our Annual
Information Form and Form 20-F for the year ended November 30, 2008, as well
as in our other public filings, including our Management's Discussion and
Analysis for the period ended May 31, 2009. The forward-looking statements are
made as of the date hereof, and we disclaim any intention and have no
obligation or responsibility, except as required by law, to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.
    This communication may be deemed to be solicitation material in respect
of the proposed transaction between IPC and Vasogen. The joint proxy circular
will be mailed to the shareholders of Vasogen and IPC. Shareholders are urged
to read the joint proxy circular when it becomes available because it will
contain important information not contained in this release about Vasogen,
IPC, and the proposed transaction.
    Applicable public documents filed by Vasogen with applicable securities
authorities in Canada and The Securities and Exchange Commission (SEC) in the
U.S., may be obtained free of charge at the SEDAR website in Canada at or at the SEC web site in the U.S. at In addition,
Vasogen shareholders may obtain free copies of the documents filed with
applicable Canadian securities authorities and the SEC by Vasogen by
contacting Vasogen Investor Relations by e-mail at or by
telephone at (905) 817-2000.
    Vasogen and its respective directors and executive officers may be deemed
to be participants in the solicitation of proxies from its shareholders in
favor of the proposed transaction. Information about the directors and
executive officers of Vasogen and their respective interests in the proposed
transaction will be available in the joint proxy circular.
    %SEDAR: 00001047E          %CIK: 0001042018

For further information:

For further information: Investor Relations, 4 Robert Speck Parkway,
15th Floor, Mississauga, ON L4Z 1S1, tel: (905) 817-2002, fax: (905) 847-6270,,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890